This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
PAHC or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PAHC vs. ABT: Which Stock Is the Better Value Option?
Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Hold IART Stock in Your Portfolio Now
by Zacks Equity Research
Integra's strong growth in the Tissue Technologies and CSS business segment bolsters investors' confidence in the stock.
Is EXAS Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.
ACB Stock Likely to Gain From Genome BC-Funded Aroma Research Project
by Zacks Equity Research
Aurora Cannabis' new collaboration on the Genome BC-Funded Project addresses distinct cannabis aromas.
Is it the Right Time to Hold EW Stock in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.
Here's Why You Should Retain BRKR Stock in Your Portfolio Now
by Zacks Equity Research
Bruker's robust growth potential across its Nano segment is encouraging. Yet, unfavorable currency movement is likely to pose a challenge.
Here's Why You Should Add BSX Stock to Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive MedSurg market share gain.
TMO Stock Likely to Gain From New International CorEvitas AD Registry
by Zacks Equity Research
Thermo Fisher launches international CorEvitas clinical registry in adolescent AD.
Global Expansion, Strategic Innovations Aid Boston Scientific Stock
by Zacks Equity Research
We are impressed with BSX's recent acquisitions that have added numerous products with immense potential.
t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock
by Zacks Equity Research
By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.
TMO Stock Gains From Innovation Amid Macroeconomic Issues
by Zacks Equity Research
Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
by Zacks Equity Research
BIO strategically expands its ddPCR platform while eyeing global expansion and benefiting from its clinical diagnostics arm.
RMD Stock Likely to Gain From Enhanced Digital Sleep Health Solutions
by Zacks Equity Research
ResMed introduces digital and personalized solutions designed to improve sleep health.
3 MedTech Stocks to Buy as Monetary Policy Eases
by Urmimala Biswas
Here, we pick three MedTech stocks, VCYT, BSX and PAHC, which are anticipated to gain strongly in 2024 from the loosening of monetary policy.
Positive Trial Outcome for PulseSelect PFA Likely to Boost MDT Stock
by Zacks Equity Research
Medtronic presents new clinical data on the PulseSelect PFA System and marks its launch in Japan.
Phibro (PAHC) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QGEN Stock to Gain From New IVDR Win for QIAstat-Dx Systems and Panels
by Zacks Equity Research
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays.
MDT Stock Might Gain From Expanded AiBLE Ecosystem and New Partnership
by Zacks Equity Research
Medtronic expands AiBLE spine surgery ecosystem with new technologies and a partnership with Siemens Healthineers.
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Industry Outlook Highlights Boston Scientific, Baxter International, Haemonetics and Phibro Animal Health
by Zacks Equity Research
Boston Scientific, Baxter International, Haemonetics and Phibro Animal Health are part of the Zacks Industry Outlook article.
Exclusive Partnership With Pair Eyewear Likely to Support EYE Stock
by Zacks Equity Research
National Vision's America's Best stores become the exclusive retail partner of Pair Eyewear.
LH Stock Likely to Gain From the Molecular Bioanalytical Lab Expansion
by Zacks Equity Research
Labcorp expands the molecular bioanalytical laboratory in Greenfield, IN.
4 Medical Product Stocks to Buy From a Prospective Industry
by Indrajit Bandyopadhyay
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors.